Latest News

Wednesday, November 25, 2015 | Medical Studies

Largest Prospective Study Evaluating the Effect of Vigabatrin on Vision

The largest prospective study evaluating vision changes in adult patients with refractory complex partial seizures (rCPS) will be available to view next month at the annual meeting of the American Epi…

Read the full story

Wednesday, November 25, 2015 | Medical Studies

Prevalence of Laser Vision Correction in Ophthalmologists Who Perform Refractive Surgery

Ophthalmologists who perform LVC were significantly more likely than the general population to have LVC in their own eyes. The prevalence of refractive errors was significantly higher among ophthalmol…

Read the full story

Wednesday, November 25, 2015 | Medical Studies

New Strategies but Modest Benefit in Uveal Melanoma

Uveal melanoma is a rare form of melanoma and is difficult to treat, with low response rates to therapies currently in use. Findings from two small studies that investigated two treatment strategies i…

Read the full story

Wednesday, November 25, 2015 | Medical Studies

Neural Deficit Progresses After Collagen Crosslinking for Keratoconus

Collagen crosslinking (CXL) treatment appears to halt the progression of keratoconus in young patients, but nerve disorientation persists, according to European investigators. Dr. Neil Lagali, who wor…

Read the full story

Tuesday, November 24, 2015 | Conferences, Envision

Envision Raises $322K at Annual Gala

At its eighth annual “Evening with Envision” gala held at the Hyatt Regency Wichita on October 23, Envision raised more than $322,000 in support of its mission to improve the quality of li…

Read the full story

Tuesday, November 24, 2015 | Partnerships, Imprimis Pharmaceuticals

Nvision Eye Centers Sign National Account Agreement for Imprimis Pharmaceuticals' Ophthalmic Compounded Formulations

Imprimis Pharmaceuticals and Nvision Eye Centers, one of the largest US providers of LASIK and cataract surgery, announced they have entered into an agreement to provide Nvision Eye Center patients wi…

Read the full story

Tuesday, November 24, 2015 | Clinical Trials, Ocular Therapeutix

Ocular Therapeutix Begins Enrollment in its Second Phase 3 Clinical Trial for Dextenza for the Treatment of Allergic Conjunctivitis

Ocular Therapeutix announced enrollment of the first patients in a second phase 3 clinical trial to evaluate the safety and efficacy of Dextenza (sustained release dexamethasone), 0.4mg intracanalicul…

Read the full story

Tuesday, November 24, 2015 | Product Releases, Nidek

Nidek Launches Tonoref III Auto Ref/Kerato/Tono/Pachymeter

Nidek has announced the launch of the Tonoref III Auto Ref/Kerato/Tono/Pachymeter, according to a company news release. The Tonoref III combines the functionality of an auto-refractometer, auto-…

Read the full story

Monday, November 23, 2015 | Clinical Trials, Alimera Sciences

Alimera Sciences Announces New 36-Month Analysis That Shows Iluvien Slows Diabetic Retinopathy Progression

Alimera Sciences announced that a new analysis of patients from the FAME Study demonstrated a significant slowing of the progression of diabetic retinopathy (DR) in patients with diabetic macular edem…

Read the full story

Monday, November 23, 2015 | Medical Studies

New Dry Eye Gel Improves Some, but Not All, Symptoms

Treating patients with dry eye syndrome for 4 weeks with carbomer-based lipid-containing artificial tear formulations (CBLAT) on top or instead of their usual artificial tear treatment improved their …

Read the full story

Monday, November 23, 2015 | Acquisitions/Mergers, Allergan

Pfizer and Allergan to Combine in $160 Billion Deal

Pfizer and Allergan announced Monday that the companies entered into a definitive merger agreement to combine in a stock transaction valued at a total enterprise value of about $160 billion, or $363.6…

Read the full story

Friday, November 20, 2015 | Management/Leadership, NovaBay Pharmaceuticals

NovaBay Pharmaceuticals Announces Restructuring to Focus on Avenova Commercialization

NovaBay Pharmaceuticals announced a corporate restructuring to focus on the commercialization of its prescription Avenova Lid and Lash Cleanser. NovaBay is also taking steps to reduce operating expens…

Read the full story

Thursday, November 19, 2015 | Glaucoma

Glaukos Submits IND Application to FDA to Study iDose Travoprost Intraocular Implant in Glaucoma Patients

Glaukos announced that it has submitted an investigational new drug (IND) application to the FDA seeking authorization to study its travoprost intraocular implant with the iDose delivery system for in…

Read the full story

Thursday, November 19, 2015 | Grants/Awards

Paragon BioTeck Announces Call For 2016 Koch Kellan Scholarship Applicants

Paragon BioTeck announced a call for applications for the 2016 Koch Kellan Scholarship, which is awarded to a deserving full-time doctoral candidate in ophthalmology, according to a company news…

Read the full story

Thursday, November 19, 2015 | Acquisitions/Mergers, Allergan

Pfizer and Allergan Said To Be Near Agreement in Deal Worth Up To $150 Billion

Pfizer and Allergan are in advanced talks to merge in a deal worth as much as $380 per share, according to several reports, which would value Allergen at as high as $150 billion. Such a deal would be …

Read the full story
Load More
 Stock Price  Change 
 Aerie Pharmaceuticals, Inc. $27.63  4.30% 
 Akorn, Inc. $33.56  2.35% 
 Alimera Sciences, Inc. $3.14  0.32% 
 Allergan $320.26  2.84% 
 Avalanche Biotechnologies $9.95  4.63% 
 Bayer $132.30  0.61% 
 Can-Fite Biopharma $3.38  10.10% 
 Carl Zeiss Meditec $26.06  0.25% 
 Cooper Companies, Inc. $145.31  0.67% 
 Eleven Biotherapeutics $3.13  4.68% 
 Escalon Medical Corp. $1.15  5.34% 
 Essilor International $129.30  0.00% 
 Glaukos $26.87  2.01% 
 Imprimis Pharmaceuticals, Inc. $6.36  0.63% 
 Inotek Pharmaceuticals $11.18  0.90% 
 InSite Vision, Inc. $0.35  0.00% 
 IRIDEX Corporation $9.68  0.41% 
 Johnson & Johnson $101.96  -0.08% 
 Luxottica Group, S.p.A. $65.61  0.12% 
 Merck & Company, Inc. $53.72  0.45% 
 NicOx $1.56  -2.68% 
 NovaBay Pharmaceuticals, Inc. $0.15  4.31% 
 Novartis AG Common Stock $85.95  -0.52% 
 Ocular Therapeutix $9.85  12.70% 
 Ophthotech Corporation $63.22  3.45% 
 QLT $2.77  1.47% 
 Quantel $2.93  -0.34% 
 Regeneron $561.69  -1.02% 
 Roche $33.19  0.90% 
 Second Sight Medical Products $4.83  -1.83% 
 Shire $208.25  -0.36% 
 STAAR Surgical Company $8.50  -0.35% 
 TearLab Corporation $1.53  0.00% 
 Thrombogenics $4.35  0.00% 
 Topcon Corporation $14.05  0.00% 
 Valeant Pharmaceuticals $87.02  -0.49% 
 Xoma $1.37  2.24%